The Oncomine database revealed high levels of ECT2 in HCC, prostate cancer, breast cancer, colon cancer, head and neck cancer, lung cancer, and stomach cancer (Fig. 2G). This evidence concerns the gene ECT2 and hepatocellular carcinoma.